Synthetic and Engineering Biology: A joint opportunity for the UK and Switzerland

Informed by roundtable discussions held at the Synthetic & Engineering Biology British-Swiss Summit, the Synthetic & Engineering Biology: A joint opportunity for the UK and Switzerland report, published in September 2024, delves into the most pressing challenges for advancing synthetic and engineering biology technologies addressing climate and environmental issues, and poses specific recommendations to governments, industry and the entire innovation ecosystem to act upon.

This webinar, which took place on 22 October 2024, saw Kerstin Kinkelin (Bristol BioDesign Institute), Maddie Cass (BIA), and Anike Te (Lucideon) discuss the report and its recommendations.

These findings are intended for a variety of stakeholders with the aim of moving forward joint Swiss and UK challenges in the field of synthetic and engineering biology, and – in light of the climate crisis – emphasising the urgent need to accelerate the commercialisation of these technologies.

The Summit was organised by the Bristol BioDesign Institute (University of Bristol), the Swiss Business Hub UK & Ireland, the BIA, and Lucideon.

Bristol hosts Swiss-British Summit to drive innovation in healthcare and sustainability

The Bristol BioDesign Institute co-hosted the Synthetic & Engineering Biology British-Swiss Summit at Bristol’s M-Shed on 22 May 2024. The inaugural event was devoted to understanding the opportunities presented by engineering biology technologies to drive innovation in healthcare, forging collaborations between Switzerland and the UK with a focus on environmental sustainability.

Ambassador Markus Leitner makes the opening address

The UK and Switzerland are both science superpowers. Collectively, they host ten of Europe’s top 20 research universities. Switzerland has ranked first in global innovation for the past decade and is home to several world-class research laboratories and multinational companies like Novartis. While the UK boasts a world-leading engineering biology community and forward-thinking policy, exemplified by the UK Government’s National Engineering Biology Vision published in December 2023.

Dr Sara Holland (Potter Clarkson), Dr Chrysi Sergaki (Medicines and Healthcare products Regulatory Agency) and Prof Imre Berger (University of Bristol) discuss commercialising research

Memorandum of Understanding signed in November 2022 between the UK and Switzerland builds on a longstanding history of collaboration between the two countries, with detailed aspirations to encourage future cooperation in ‘deep science’ and ‘deep tech’ areas such as engineering biology.

The Summit, organised in partnership with the Swiss Business Hub UK & Ireland, the BioIndustry Association and Lucideon, aimed to bring together academic thought leaders and representatives from the life science and pharmaceutical industries. These included key Government officials, including members of the UK Government’s newly appointed Engineering Biology Steering Committee regulators, specialist start-up incubators such as Science Creates (Bristol) and BaseLaunch (Basel), and focused investment firms to identify bilateral opportunities for commercialisation through innovation, and policy and diplomacy in science and innovation.

His Excellency Markus Leitner, Ambassador of Switzerland to the United Kingdom said: “The United Kingdom and Switzerland are uniquely placed to work together on this frontier of scientific discovery and technological innovation.

“Bringing together scientists, industry leaders and start-up entrepreneurs from both countries will foster the exchange of ideas, forge new partnerships, and catalyse new initiatives that will shape the future of synthetic and engineering biology.”

Anike Te chairs debate on cell engineering

The Summit took a deep dive into future perspectives in cell engineering, bioprocessing and scale up, AI-driven solutions in synthetic and engineering biology, and accelerating the translation of fundamental research to commercial uptake.

Anike Te, Aegis Professor of Engineering Biology at the University of Bristol and Chief Strategy Officer at Lucideon, added: “Innovation is essential for solving the global challenges we face today. Engineering biology has the potential to provide many of these solutions. The UK and Switzerland are important countries for innovation and it is inspiring to see more collaboration in synthetic and engineering biology.”

Tay Salimullah during his opening keynote address

Inspiring keynote talks were presented by Tay Salimullah (right), VP, Head US & Global Commercial, Value & Access, and Member of the Executive Committee at Novartis Gene Therapies and Dr Harry Destecroix, founder of Science Creates and co-founder of Ziylo, the hugely successful University of Bristol spin-out company.

Spotlight pitches from UK and Swiss engineering biology start-ups highlighted some of the most recent innovations entering the market.

(All images: First Avenue Photography)

(The news story was first published by University of Bristol)

SBUK 2023 takes place in Bristol

Over 300 people from 45 institutions in 11 countries attended the Synthetic Biology 2023 conference in Bristol on 6-7 November, organised by the Biochemical Society and the Bristol BioDesign Institute.

We would like to thank all the invited speakers (Prof Patrick CaiProf Tanja KortemmeProf Petra SchwilleProf Andreas PlückthunProf Susan RosserProf Seraphine WegnerProf Julius LucksDr David RiglarDr Nicole Wheeler and Dr Gitta Neufang), the oral and poster presenters, the session chairs, the team from the Biochemical Society, and everyone else who attended for their help in making the event a great success.

Themes covered at the conference included biomolecular design and engineering; cell and system-level design; synthetic and minimal cells; data-centric bioengineering, and applications across industry.

Dek Woolfson presents Stephen Wallace with the Colworth Medal.Congratulations to Prof Stephen Wallace, who was awarded the prestigious Colworth Medal and gave a talk on the development of ‘plastic-eating E. coli that can efficiently turn polyethylene terephthalate (PET) waste into adipic acid, which is used to make nylon materials, drugs and fragrances’.

Further congratulations to the oral and poster prize recipients:

Synthetic Biology UK 2023

The Biochemical Society and the Bristol BioDesign Institute are working together to organise this year’s Synthetic Biology UK meeting, which will take place in Bristol on 6-7 November.

Registration is now open. The deadline for submitting abstracts (and for early registration) is Wednesday 6 September 2023. 

Synthetic biology is a maturing field at the confluence of the biosciences, physical sciences, information technology, and engineering and is rapidly beginning to demonstrate valuable solutions to some of our most pressing global challenges in healthcare, agriculture, sustainability and the environment.

SBUK 2023 will bring the synthetic and engineering biology communities together in Bristol, a city with a rich and long-standing history in engineering and a vibrant research community in synthetic biology, to share recent scientific advancements across the field. Conference themes will include biomolecular design and engineering; cell and system-level design; synthetic and minimal cells; data-centric bioengineering, and applications across industry.

The diverse and inclusive programme will include opportunities for networking, and an emphasis will be placed on ensuring the event offers early career researchers with the vital opportunities needed to build their wider research networks with leading experts in the field, as well as gain insights into careers in industry, SMEs, policy, academia and innovation delivery.

Confirmed speakers include: Prof Patrick Cai, Prof Tanja Kortemme, Dr Gitta Neufang, Prof Andreas Plückthun, Dr David Riglar, Prof Susan Rosser, Prof Petra Schwille, Prof Seraphine Wegner, Prof Julius Lucks, and Dr Nicole Wheeler.

Banner contains details of the date, venue and website of the SBUK conference.

Bristol’s pioneering COVID-19 research prompts French Embassy visit

Representatives from the French Embassy visited University labs on 10 December to see some of the innovative COVID-19 research being undertaken at Bristol, including work on ADDomer™, a thermostable vaccine platform being developed by Bristol scientists to combat emerging infectious diseases.

Dr Rachel Millet and Arthur Belaud from the Embassy’s Innovation Branch, which seeks to drive France-UK business enterprise, met with scientists Professor Imre Berger and Frederic Garzoni, founders of Imophoron Ltd, the biotech start-up developing ADDomer that uses technology developed at an institution in France, and recently secured £4 million investment.

L to R: Arthur Belaud from the French Embassy, Dr Anne Westcott from the University, Dr Rachel Millet from the French Embassy and Professor Imre Berger at the University’s Max Planck Bristol Centre for Minimal Biology.

During the visit, the delegation took a tour of labs in the University’s Max Planck-Bristol Centre for Minimal Biology (MPBC), the GW4/Wellcome Trust Cryo-EM facility led by Prof Christiane Schaffitzel, and Science Creates, the Bristol-based incubator, which is operated in partnership with the University and supports scientists and engineers in commercialising ground-breaking innovations. Having recently opened its second facility in the city’s Old Market, the party met with Science Creates founder and Bristol graduate Dr Harry Destecroix to discuss the future of deep-tech eco-systems.

Professor Imre Berger, Director of Bristol’s Max Planck Centre for Minimal Biology, said: “We are honoured to host this visit from the French Embassy’s Innovation Branch to share knowledge and showcase the pioneering research that is being done in collaboration with our European colleagues and institutions.”

Press release issued: 10 December 2021 on University of Bristol News and Features~ article here.

A spotlight on Plant Synthetic Biology – BBI Webinar

This webinar is a spotlight on plant synthetic biology, featuring three rising stars in one dynamic interactive session. Three early career researchers, hosted by Dr. Thomas Gorochowski and Dr. Emily Larson, discuss plant biology topics including reprogramming plant root growth, genome engineering, and the biodesign potential of marchantia polymorpha. The speakers include:

  • Dr. Jennifer Brophy (keynote) – ‘Reprogramming plant root growth using synthetic developmental regulation.’
  • Dr Quentin Dudley – ‘Genome engineering of Nicotiana benthamiana as an improved plant-based bioproduction system for medicinal alkaloids.’
  • Dr Eftychis Frangedakis – ‘Marchantia polymorpha: an emerging system for plant synthetic biology.’

You can watch the full recording, including Q&A here:

BBI International Webinar Series – Professor Elisa Franco, UCLA

The Bristol BioDesign Institute‘s newly imagined webinar series for 2021 has been designed as a platform to invite the best international speakers that are aligned to our core areas of interest. These include; biomolecular design and assembly in the cell, development and delivery of bioactive molecules, minimal biology towards cell-like systems, advanced computing and digital biology. You can find our upcoming speakers for the year on the International Webinar Series section of our website.

The first speaker of 2021 is Professor Elisa Franco from UCLA, with BBI Directors, Thomas Gorochowski and Dek Woolfson, panelling. The seminar is followed by an audience Q&A session, and then a one-to-one interview where Dr. Gorochowski asks Professor Franco questions about how she got into synthetic biology and her predictions for its future. 

You can watch Professor Franco’s seminar, on ‘Programming dynamic behaviors in molecular systems and materials‘ below, or on the BBI YouTube Channel.

Abstract – Biological cells adapt, replicate, and self-repair in ways that are unmatched by man-made devices. These processes are enabled by the interplay of receptors, gene networks, and self-assembling cytoskeletal scaffolds. Taking inspiration from this architecture, we follow a reductionist approach to build synthetic materials by interconnecting nucleic acid components with the capacity to sense, compute, and self-assemble. Nucleic acids are versatile molecules whose interactions and kinetic behaviors can be rationally designed from their sequence content; further, they are relevant in a number of native and engineered cellular pathways, as well as in biomedical and nanotechnology applications. I will illustrate our approach with two examples. The first is the construction of self-assembling DNA scaffolds that can be programmed to respond to environmental inputs and to canonical molecular signal generators such as pulse generators and oscillators. The second is the encapsulation of these dynamic scaffolds in droplets serving as a mimic of cellular compartments. I will stress how mathematical modeling and quantitative characterization can help identify design principles, guide experiments, and explain observed phenomena.

BBI Webinar: Professor Domitilla Del Vecchio, MIT

Since the start of lockdown 1.0 in March 2020, the BBI has been hosting a series of virtual seminars. Speakers have included Professors Anne Osbourn, Christine Orengo, Andreas Plueckthun, and many others. Lockdown has allowed us to broaden our speaker base on an international level, with academics from the US, Israel and Switzerland.

On 11 November, we had Professor Domitilla Del Vecchio from the Massachusetts Institute of Technology (MIT) give a webinar on ‘Context dependence of biological circuits: Predictive models and engineering solutions’. Panellists for the event were some of our own University of Bristol academics Dr. Thomas Gorochowski and Prof. Claire Grierson.

You can watch the full recording of the webinar here:

DNA gets cool – the world of nucleic acid biomachinery.

Written by SynBio CDT students Claire Noble and Harry Thompson.

Do we have any chance of designing new ribosomes from scratch? Maybe not just yet, but that doesn’t mean Jon Bath, from the University of Oxford, isn’t getting started. While DNA origami hasn’t always been as glamorous as the world of protein design, that doesn’t mean there isn’t lots of exciting potential for new, DNA-based biomachinery.

The relatively simple nature of DNA folding based on base pairing has allowed for the construction of intricate and beautiful DNA structures. However, the field of designing DNA structure towards novel functionality is still being explored. In the past, DNA has been shown to be capable of moving along short tracks and assembling simple polymers in a directed way. Jon Bath is seeking to gain a deeper fundamental understanding of what dictates higher level folding in DNA origami, so that more complex designs can be attempted. He is making use of comparatively ‘simple’ DNA structures, with uncommon motif’s such as T-junctions, to try and elucidate the mechanisms behind self-assembly of complex origami.

By increasing our understanding of how DNA folds, design principles can then be applied towards constructions of functional origamis, of which there have been relatively few examples so far. A brave new world of DNA templated chemistry and molecular motors awaits!